February 5, 2014
Audentes Therapeutics and Genethon Announce Agreement to Develop Treatment for Severe Genetic Disease X‐Linked Myotubular Myopathy
SAN FRANCISCO, CA – February 5, 2014 –Audentes Therapeutics, Inc., a biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, and Genethon, a non‐profit organization dedicated to the research and development of biotherapies for orphan genetic diseases, announce that they have… (read more)
January 23, 2014
Efficacy of gene therapy demonstrated in canine and murine models of myotubular myopathy
Evry (France), 22 January, 2014. A team of French researchers, led by Dr. Ana Buj-Bello (Genethon/Inserm) and teams at the University of Washington and Harvard Medical School in the United States, have demonstrated the efficacy of gene therapy in models of myotubular myopathy, an extremely severe neuromuscular disease in children. Transfer of… (read more)
June 27, 2013
Généthon, the French AFM-Telethon laboratory, becomes the first not-for-profit to obtain authorization from ANSM to be a pharmaceutical manufacturer
Evry, June 27, 2013. Généthon, the AFM-Telethon laboratory, has received the authorization delivered by
the National Agency for Drug Safety (ANSM) to become a pharmaceutical manufacturer. Its production
center, Généthon BioProd, is now authorized to produce drugs for innovative treatments. This is a first
for a laboratory created… (read more)
June 24, 2013
The European charity Myotubular Trust is supporting Généthon in developing gene therapy for myotubular myopathy
The European charity Myotubular Trust announces its support to the development of a pre-clinical gene therapy trial for myotubular myopathy.
(read more)February 5, 2013
Genethon receives approval from the UK medicine regulatory agency to start a new clinical trial for an inherited immune deficiency: chronic granulomatous disease
On January 10th, the British Medicine and Healthcare Regulatory Agency (MHRA) approved Genethon’s Phase I / II gene therapy clinical trial application in X-linked chronic granulomatous disease (XCGD) to start at Great Ormond Street Hospital in London. Genethon is also seeking approval for this multicenter trial in Germany, Switzerland and… (read more)
November 8, 2012
Decree “advanced therapy medicinal products”: a new milestone for the AFM-Telethon and laboratory Genethon!
The decree relating to “advanced therapy medicinal products” was published in the Journal Officiel on 8 November. A decree awaited since the adoption of the Law of 22 March 2011 allowing organizations to become non-profit pharmaceutical establishments. In the coming days, Genethon submit its application for accreditation by the… (read more)
October 5, 2012
Genethon receives the 2012 Prix Galien France
Genethon receives the 2012 Prix Galien France for its innovative treatments of rare diseases using gene therapy and awarded it the prize in the category of “Medicines destined for rare diseases – cell therapy and gene therapy.” For the first time, a non-profit organization, created by a patient association, has received the Prix… (read more)
September 27, 2012
Genethon, member of the Biotherapies Institute for Rare Diseases
The Biotherapies Institute for Rare Diseases, a unique task force to accelerate therapeutic developments, includes 4 laboratories founded and supported by the AFM Telethon : the Institute of Myology, Genethon, I-Stem and Atlantic Gene Therapies (Nantes’ gene therapy research centre).
(read more)July 4, 2012
Alain Schwenck, an Expert on Pharmaceutical Prodcution, becomes Director of Genethon Bioprod
Alain Schwenck, 51, has joined Genethon as Director of Genethon Bioprod, the new site for the production of clinical grade-gene therapy medicines for the treatment of rare diseases, created by AFM-Telethon.
(read more)January 17, 2012
Fulvio Mavilio, the internationally acknowledged expert in gene therapy for rare diseases, is appointed as Genethon’s new Scientific Director
Fulvio Mavilio, PhD is appointed as the new Scientific Director of Généthon.
(read more)January 12, 2012
Gene therapy : Encouraging results in a Phase I clinical trial in limb-girdle muscular dystrophy type 2C
The results of a Phase I clinical trial of gene therapy for limb-girdle muscular dystrophy type 2C (a rare neuromuscular disease) have just been published in the journal Brain on January 11, 2012.
(read more)September 1, 2011
On the Internet site of the Usine Nouvelle magazine you can discover the Genethon laboratory financed by donations to the Telethon through images from behind the scenes
Both clear and comprehensive, this document will take you to the heart of gene therapy.
(read more)July 21, 2011
Genethon and Children’s Hospital Boston get FDA approval for a Wiskott Aldrich gene therapy trial
The US Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS).
(read more)March 8, 2011
Genethon and Wake Forest University School of Medicine (North Carolina) announce their collaboration for a preclinical gene therapy trial
Evry (France), March 8th, 2011 – Genethon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (Association Française contre les Myopathies, AFM) with donations from France’s annual Telethon) and Wake Forest University School of Medicine (Winston Salem, North Carolina, USA)… (read more)
January 5, 2011
Partnership for a gene therapy Clinical trial signed between Genethon and Children’s Hospital Boston
A unique multicenter international study of gene therapy for a rare genetic disease (Wiskott-Aldrich syndrome) led in London, Paris and Boston.
(read more)